Literature DB >> 16700813

Airway selectivity: an update of pharmacokinetic factors affecting local and systemic disposition of inhaled steroids.

Staffan Edsbäcker1, Carl-Johan Johansson.   

Abstract

Topical corticosteroids remain the most efficacious single treatment for asthma and rhinitis, despite the emergence of newer drugs in recent years. The antiinflammatory properties of these products, combined with the targeting of formulations and optimization of the intrinsic pharmacokinetic features of the newer corticosteroid molecules has resulted in substantially improved airway selectivity. This review sets out to summarize the pharmacokinetic properties of inhaled corticosteroids that are important for the achievement of high levels of airway selectivity, with additional focus on the use of prodrugs/softdrugs relative to those of conventional corticosteroid molecules, mechanisms (such as esterification) by which retention at the target site is achieved while minimizing systemic exposure, and the role of plasma protein binding.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16700813     DOI: 10.1111/j.1742-7843.2006.pto_355.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  10 in total

1.  In vitro aqueous fluid-capacity-limited dissolution testing of respirable aerosol drug particles generated from inhaler products.

Authors:  Deepika Arora; Kumar A Shah; Matthew S Halquist; Masahiro Sakagami
Journal:  Pharm Res       Date:  2010-03-13       Impact factor: 4.200

2.  Evaluating the suitability of using rat models for preclinical efficacy and side effects with inhaled corticosteroids nanosuspension formulations.

Authors:  Po-Chang Chiang; Yiding Hu; Jason D Blom; David C Thompson
Journal:  Nanoscale Res Lett       Date:  2010-04-10       Impact factor: 4.703

Review 3.  Safety of inhaled budesonide: clinical manifestations of systemic corticosteroid-related adverse effects.

Authors:  Camilla Christensson; Anders Thorén; Bengt Lindberg
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate.

Authors:  Zia R Tayab; Tom C Fardon; Daniel K C Lee; Kay Haggart; Lesley C McFarlane; Brian J Lipworth; Günther Hochhaus
Journal:  Br J Clin Pharmacol       Date:  2007-05-17       Impact factor: 4.335

5.  Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study.

Authors:  Shohei Kawachi; Keisaku Fujimoto
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-05-27

Review 6.  Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects.

Authors:  You Xu; Aneesh Thakur; Yibang Zhang; Camilla Foged
Journal:  Pharmaceutics       Date:  2021-01-28       Impact factor: 6.321

7.  Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein.

Authors:  Nigel Davies; Daniel Hovdal; Nicholas Edmunds; Peter Nordberg; Anders Dahlén; Aleksandra Dabkowska; Marianna Yanez Arteta; Aurel Radulescu; Tomas Kjellman; Andreas Höijer; Frank Seeliger; Elin Holmedal; Elisabeth Andihn; Nils Bergenhem; Ann-Sofie Sandinge; Camilla Johansson; Leif Hultin; Marie Johansson; Johnny Lindqvist; Liselotte Björsson; Yujia Jing; Stefano Bartesaghi; Lennart Lindfors; Shalini Andersson
Journal:  Mol Ther Nucleic Acids       Date:  2021-03-13       Impact factor: 8.886

8.  Applicability of RPMI 2650 and Calu-3 Cell Models for Evaluation of Nasal Formulations.

Authors:  Nadica Sibinovska; Simon Žakelj; Jurij Trontelj; Katja Kristan
Journal:  Pharmaceutics       Date:  2022-02-06       Impact factor: 6.321

Review 9.  Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes.

Authors:  Jens Markus Borghardt; Charlotte Kloft; Ashish Sharma
Journal:  Can Respir J       Date:  2018-06-19       Impact factor: 2.409

10.  Use of PBPK Modeling To Evaluate the Performance of Dissolv It, a Biorelevant Dissolution Assay for Orally Inhaled Drug Products.

Authors:  Mireille Hassoun; Maria Malmlöf; Otto Scheibelhofer; Abhinav Kumar; Sukhi Bansal; Ewa Selg; Mattias Nowenwik; Per Gerde; Snezana Radivojev; Amrit Paudel; Sumit Arora; Ben Forbes
Journal:  Mol Pharm       Date:  2019-02-15       Impact factor: 4.939

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.